Efficacy and safety of imeglimin add‐on to DPP ‐4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double‐blind FAMILIAR trial

Documenti analoghi

• Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data‐driven cluster analysis: A post‐hoc analysis of imeglimin clinical trial data
  di: Katsuhiko Hagi, et al.
  Pubblicazione: (2024)
• Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice
  di: Yuichiro Iwamoto, et al.
  Pubblicazione: (2024)
• Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
  di: Da Hea Seo, et al.
  Pubblicazione: (2025)
• Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial
  di: Nan Yu, et al.
  Pubblicazione: (2025)
• A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial
  di: Qinghua He, et al.
  Pubblicazione: (2024)